Plain-English translation of NCT05303519 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called to see if it can help slow down or prevent the growth of certain brain tumors that have a specific genetic change (an IDH1 mutation). The trial has three parts: the first part tests different doses to find the safest and most effective dose, the second part tests whether the medication prevents tumors from coming back after standard treatment, and the third part tests it in people with a specific type of tumor that has returned or is growing.
Brain tumors with this specific genetic mutation are hard to treat, and even after standard therapies like radiation and chemotherapy, they often come back. This trial is trying to find out if this medication can help prevent that recurrence and improve survival.
You likely qualify if…
You likely don't qualify if…
If you join Part 1 (the dose-finding phase), you would take the medication by mouth once or twice daily and visit the clinic regularly so doctors can monitor you with blood tests and imaging. If you're in Part 2 or Part 3 (the main treatment phases), you would take the medication twice daily by mouth in 28-day cycles and continue until your tumor progresses or you need to stop for another reason, with regular clinic visits and imaging to track how your tumor is responding.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States